RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
复制标题
DOI：
10.1038/s41392-020-00402-5
复制
发表时间：
2020-11-27
影响因子：
39.3
通讯作者：
Jiang S
中科院分区：
文献类型：
--
作者：
Liu Z;Xu W;Xia S;Gu C;Wang X;Wang Q;Zhou J;Wu Y;Cai X;Qu D;Ying T;Xie Y;Lu L;Yuan Z;Jiang S
由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）大流行对全球健康和经济构成严重威胁，因此需要开发安全有效的疫苗。SARS-CoV-2刺突蛋白的受体结合域（receptor-binding domain，RBD）负责与血管紧张素转换酶2（angiotensin-converting enzyme 2，ACE 2）受体的结合。它含有多个优势中和表位，是开发COVID-19疫苗的重要抗原。在这里，我们表明，用由SARS-CoV-2 RBD和人IgG的Fc片段组成的候选亚单位疫苗作为免疫增强剂免疫小鼠，引起高滴度的RBD特异性抗体，其对假型和活的SARS-CoV-2感染具有稳健的中和活性。小鼠抗血清也能有效地中和具有几个天然突变的假型SARS-CoV-2的感染，从小鼠抗血清中提取的IgG也能中和假型SARS-CoV和SARS-related coronavirus（SARS-Sr-CoV）。用RBD-Fc免疫人ACE 2转基因小鼠可有效保护小鼠免受SARS-CoV-2攻击。这些结果表明，SARS-CoV-2 RBD-Fc具有良好的潜力，可以进一步开发为有效和广谱的疫苗，以预防当前SARS-CoV-2及其突变体的感染，以及未来新出现的SARS-CoV和重新出现的SARS-CoV。
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy, thus calling for the development of safe and effective vaccines. The receptor-binding domain (RBD) in the spike protein of SARS-CoV-2 is responsible for its binding to angiotensin-converting enzyme 2 (ACE2) receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that immunization of mice with a candidate subunit vaccine consisting of SARS-CoV-2 RBD and Fc fragment of human IgG, as an immunopotentiator, elicited high titer of RBD-specific antibodies with robust neutralizing activity against both pseudotyped and live SARS-CoV-2 infections. The mouse antisera could also effectively neutralize infection by pseudotyped SARS-CoV-2 with several natural mutations in RBD and the IgG extracted from the mouse antisera could also show neutralization against pseudotyped SARS-CoV and SARS-related coronavirus (SARSr-CoV). Vaccination of human ACE2 transgenic mice with RBD-Fc could effectively protect mice from the SARS-CoV-2 challenge. These results suggest that SARS-CoV-2 RBD-Fc has good potential to be further developed as an effective and broad-spectrum vaccine to prevent infection of the current SARS-CoV-2 and its mutants, as well as future emerging SARSr-CoVs and re-emerging SARS-CoV.
登录
查看更多内容
DOI：
10.1038/nrmicro.2016.81
发表时间：
2016-08
期刊：
Nature reviews. Microbiology
影响因子：
--
作者：
de Wit E;van Doremalen N;Falzarano D;Munster VJ
通讯作者：
Munster VJ
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
影响因子：
3.7
作者：
Du, Lanying;Zhao, Guangyu;Chan, Chris C. S.;Sun, Shihui;Chen, Min;Liu, Zhonghua;Guo, Hongxiang;He, Yuxian;Zhou, Yusen;Zheng, Bo-Jian;Jiang, Shibo
通讯作者：
Jiang, Shibo
SARS-COV峰值蛋白的受体结合结构域可诱导高度有效的中和抗体：对开发亚基疫苗的影响。
DOI：
10.1016/j.bbrc.2004.09.106
发表时间：
2004-11-12
影响因子：
3.1
作者：
He Y;Zhou Y;Liu S;Kou Z;Li W;Farzan M;Jiang S
通讯作者：
Jiang S
影响因子：
16.6
作者：
Du, Lanying;Tai, Wanbo;Yang, Yang;Zhao, Guangyu;Zhu, Qing;Sun, Shihui;Liu, Chang;Tao, Xinrong;Tseng, Chien-Te K.;Perlman, Stanley;Jiang, Shibo;Zhou, Yusen;Li, Fang
通讯作者：
Li, Fang